AU3674895A - Estrogens and parathyroid hormone for treating osteoporosis - Google Patents

Estrogens and parathyroid hormone for treating osteoporosis

Info

Publication number
AU3674895A
AU3674895A AU36748/95A AU3674895A AU3674895A AU 3674895 A AU3674895 A AU 3674895A AU 36748/95 A AU36748/95 A AU 36748/95A AU 3674895 A AU3674895 A AU 3674895A AU 3674895 A AU3674895 A AU 3674895A
Authority
AU
Australia
Prior art keywords
osteoporosis
bone
estrogen
parathyroid hormone
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU36748/95A
Other languages
English (en)
Inventor
John Althorp Bevan
Ann Dunbar Geddes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of AU3674895A publication Critical patent/AU3674895A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AU36748/95A 1994-09-09 1995-09-06 Estrogens and parathyroid hormone for treating osteoporosis Abandoned AU3674895A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30392694A 1994-09-09 1994-09-09
US303926 1994-09-09
PCT/US1995/011386 WO1996007416A1 (fr) 1994-09-09 1995-09-06 Oestrogenes et hormone parathyroidienne utiles pour traiter l'osteoporose

Publications (1)

Publication Number Publication Date
AU3674895A true AU3674895A (en) 1996-03-27

Family

ID=23174293

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36748/95A Abandoned AU3674895A (en) 1994-09-09 1995-09-06 Estrogens and parathyroid hormone for treating osteoporosis

Country Status (8)

Country Link
EP (1) EP0804202A4 (fr)
JP (1) JP2001503728A (fr)
KR (1) KR970705397A (fr)
CN (1) CN1158569A (fr)
AU (1) AU3674895A (fr)
CA (1) CA2199250A1 (fr)
IL (1) IL115225A0 (fr)
WO (1) WO1996007416A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545635A (en) * 1995-05-23 1996-08-13 Eli Lilly And Company Inhibiting bone loss with equilenin
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
CN101355959B (zh) 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
EP2509996A1 (fr) 2009-12-07 2012-10-17 Michigan Technological University Hormone parathyroïde de l'ours noir et ses procédés d'utilisation
WO2015057836A2 (fr) * 2013-10-15 2015-04-23 The Trustees Of Columbia University In The City Of New York Hormone parathyroïdienne anabolique osseuse et analogues de protéine apparentée à l'hormone parathyroïdienne

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
TW303299B (fr) * 1993-07-22 1997-04-21 Lilly Co Eli

Also Published As

Publication number Publication date
EP0804202A1 (fr) 1997-11-05
JP2001503728A (ja) 2001-03-21
WO1996007416A1 (fr) 1996-03-14
KR970705397A (ko) 1997-10-09
CN1158569A (zh) 1997-09-03
EP0804202A4 (fr) 1999-01-13
IL115225A0 (en) 1995-12-31
CA2199250A1 (fr) 1996-03-14

Similar Documents

Publication Publication Date Title
EP1059933B1 (fr) Utilisation de l'hormone parathyroidienne composee des acides amines 1-34 de l'hormone parathyroidienne humaine pour reduire les risques de fractures osseuses vertebrales et non vertebrales
RU2112515C1 (ru) Способ лечения остеопороза
Cosman et al. Parathyroid hormone treatment for osteoporosis
US7351414B2 (en) Method of reducing the risk of bone fracture
Cunnane et al. STEROID–INDUCED OSTEOPOROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
EP1221966B1 (fr) Utilisation d'une hormone parathyroide pour reduire les risques de cancer
AU3674895A (en) Estrogens and parathyroid hormone for treating osteoporosis
AU686458B2 (en) Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
WO1999004808A1 (fr) Medicaments dentaires contenant de la pth
JPH0873376A (ja) 骨粗鬆症治療薬
AU686019B2 (en) Phosphonates and parathyroid hormone for osteoporosis
Oyoo et al. Osteoporosis--From hormonal replacement therapy to bisphosphonates and beyond: A review
Rittinghaus et al. The concept and treatment of osteoporosis
EP1769804B1 (fr) hPTH(1-34) pour son utilisation dans la prévention ou la sévérité de fractures osseuses chez le mâle humain
HK1030545B (en) Use of parathyroide hormone consisting of aminoacid sequence 1-34 of human parathyroid hormone for reducing the risk of both vertebral and non vertebral bone fracture